Tag: filgrastim biosimilars market share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Filgrastim Biosimilars Market Revenue Growth On Track For A 11.9% CAGR Through 2030

The filgrastim biosimilars market size has experienced rapid growth in recent years. It is anticipated to increase from $1.19 billion in 2025 to $1.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.5%. The expansion witnessed in the historic period can be linked to the high cost of originator filgrastim, the rising prevalence of cancer and blood disorders, constrained access to biologics in developing regions, advancing hospital infrastructure, and swift approvals of biosimilars by regulatory authorities.

The filgrastim biosimilars market size is projected to experience swift expansion over the coming years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. This anticipated growth is driven by several factors, including the introduction of advanced filgrastim biosimilars, broader contract manufacturing collaborations, increased application in chronic and autoimmune conditions, augmented government backing and reimbursement frameworks, and the evolution of patient-focused distribution and delivery strategies. Key developments expected during this period encompass the growing integration of filgrastim biosimilars in oncology and blood disorder therapies, the expansion of contract manufacturing organizations dedicated to biosimilar production, a greater reliance on internal vertically integrated manufacturing sites, a developing preference for hospital and retail pharmacy distribution channels, and a concentrated effort on affordable biologics and market accessibility in developing regions.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=38601368&type=smp&name=Filgrastim%20Biosimilars%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Filgrastim Biosimilars Market Growth Factors: What’s Supporting Expansion?

An anticipated increase in cancer cases is projected to fuel the expansion of the filgrastim biosimilars market in the future. Cancer encompasses various illnesses characterized by the unchecked proliferation and dissemination of atypical cells within the body, stemming from genetic alterations that impair regular cellular control. This surge in cancer occurrence is partially attributable to an aging populace, given that extended lifespans increase the probability of genetic mutations contributing to cancer development. Filgrastim biosimilars assist individuals with cancer by stimulating the production of white blood cells, thereby mitigating the danger of neutropenia induced by chemotherapy and facilitating safer, uninterrupted cancer therapy. For example, the National Health Service (NHS), a government health organization in the UK, reported in October 2025 that 2023 saw 354,820 new cancer diagnoses, averaging 972 daily, marking an increase of 8,605 from 2022. Consequently, the escalating rate of cancer incidence is propelling the filgrastim biosimilars market.

Filgrastim Biosimilars Market Segmentation And Category Overview

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Filgrastim Biosimilars Market Industry Trends: What’s Reshaping Demand?

Leading companies in the filgrastim biosimilar market are advancing product development by utilizing sophisticated technologies, such as recombinant DNA technology, to manufacture biosimilars. Recombinant DNA technology is a process involving the creation of hybrid or chimeric DNA by inserting an external sequence into an organism’s DNA. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched FYLNETRA (pegfilgrastim-pbbk) in the United States. This product, a biosimilar to Amgen’s NEULASTA, is indicated for both the treatment and prevention of febrile neutropenia. It works by encouraging the growth and specialization of neutrophils derived from dedicated precursor cells, triggering their maturation, and improving the viability and efficiency of fully developed neutrophils, which leads to dosage-dependent increases in neutrophil counts. The introduction of Fylnetra contributes to the next generation of affordable medications and expands access for patients, healthcare providers, and payors.

Filgrastim Biosimilars Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

View The Full Filgrastim Biosimilars Market Report:

https://thebusinessresearchcompany.com/report/Filgrastim-Biosimilar-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Filgrastim Biosimilars Market Regional Breakdown: Where Is Demand Concentrated?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Filgrastim Biosimilars Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for filgrastim biosimilars has experienced rapid expansion in recent years. Projected to climb from $1.19 billion in 2025 to $1.33 billion in 2026, this represents a compound annual growth rate (CAGR) of 11.5%. Factors driving historical growth include the elevated expense of the original filgrastim, a rise in cases of cancer and blood-related conditions, restricted availability of biologic therapies in developing areas, advancements in hospital infrastructure, and the timely authorization of biosimilars by regulatory agencies.

The filgrastim biosimilars market is projected to experience substantial expansion over the coming years, reaching an estimated value of $2.09 billion by 2030, which represents a compound annual growth rate of 11.9%. This anticipated growth during the forecast period is driven by several key factors, including the introduction of next-generation filgrastim biosimilars, the broadening of contract manufacturing partnerships, a growing rate of adoption for treating chronic and autoimmune diseases, strengthened government support combined with favorable reimbursement policies, and the creation of patient-focused distribution and delivery systems. Among the major trends shaping this period are the increasing use of filgrastim biosimilars within oncology and blood disorder therapies, the growth of contract manufacturing organizations dedicated to biosimilar production, a stronger reliance on vertically integrated in-house manufacturing setups, a rising preference for distribution through hospital and retail pharmacy channels, and an overall emphasis on delivering cost-effective biologic treatments while improving market access.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Filgrastim Biosimilars Market Growth Momentum: Which Factors Are Influencing Demand?

The growth of the filgrastim biosimilars market is anticipated to be fueled by the increasing prevalence of cancer in the coming years. Cancer encompasses a range of illnesses characterized by the abnormal proliferation and spread of cells within the body, resulting from genetic mutations that impair normal cellular regulation. The higher occurrence of cancer is partially attributed to an aging population, as longer lifespans elevate the probability of genetic mutations that can trigger the disease. By enhancing white blood cell production, filgrastim biosimilars assist cancer patients in lowering the risk of neutropenia caused by chemotherapy, thereby facilitating more consistent and safer treatment. As an example, in October 2025, the National Health Service (NHS), a government health authority in the UK, reported that 354,820 new cancer cases were diagnosed in 2023—an average of 972 per day, representing an increase of 8,605 compared to 2022. Consequently, the uptick in cancer incidence is propelling the filgrastim biosimilars market forward.

Filgrastim Biosimilars Market Segment Analysis And Revenue Opportunities

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Filgrastim Biosimilars Market Trends Reshaping Industry Growth

Leading firms within the filgrastim biosimilar space are currently focusing on the creation of innovative products that rely on advanced methodologies, including recombinant DNA technology, to manufacture biosimilars. This technology involves assembling hybrid or chimeric DNA by introducing a foreign sequence into the genetic material of an organism. As an example, in May 2023, Amneal Pharmaceuticals—a pharmaceutical company headquartered in the US—released FYLNETRA (pegfilgrastim-pbbk), a biosimilar comparable to Amgen’s NEULASTA, available in the United States for managing and preventing febrile neutropenia. This agent facilitates the growth and specialization of neutrophils from dedicated precursor cells, triggers their maturation process, and boosts both the viability and effectiveness of mature neutrophils, resulting in dose-dependent elevations in neutrophil counts. By launching Fylnetra, the next generation of cost-effective treatments is advanced, broadening access for patients, healthcare providers, and insurers alike.

Filgrastim Biosimilars Market Leading Players Shaping Industry Direction

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Access The Complete Filgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Filgrastim Biosimilars Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Filgrastim Biosimilars Market Progress Through 2030?

The filgrastim biosimilars market size has seen swift expansion in recent years. It is forecast to rise from $1.19 billion in 2025 to $1.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.5%. This historical growth is attributable to the high cost associated with originator filgrastim, an escalating prevalence of cancer and various blood disorders, constrained availability of biologics in developing regions, the development of hospital infrastructure, and the early regulatory endorsements for biosimilars.

The filgrastim biosimilars market size is anticipated to grow significantly in the coming years, reaching $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is driven by factors such as the introduction of next-generation filgrastim biosimilars, the broadening of contract manufacturing partnerships, increasing adoption in chronic and autoimmune diseases, rising government support and reimbursement policies, and the development of patient-centric distribution and delivery models. Key trends expected over the forecast duration include the increasing utilization of filgrastim biosimilars in oncology and blood disorder treatments, the expansion of contract manufacturing organizations for biosimilar production, a greater use of in-house vertically integrated manufacturing facilities, a growing preference for hospital and retail pharmacy distribution channels, and a focus on cost-effective biologics and enhanced access in emerging markets.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

Which Drivers Are Advancing The Filgrastim Biosimilars Market Growth?

An escalating incidence of cancer is anticipated to fuel the expansion of the filgrastim biosimilars market moving forward. Cancer is characterized as a collection of diseases defined by the uncontrolled proliferation and dispersion of atypical cells throughout the body, triggered by genetic mutations that disrupt normal cellular regulation. The growing occurrence of cancer is partially due to an aging population, as individuals live longer and face a greater likelihood of developing genetic mutations that can lead to cancer. Filgrastim biosimilars assist cancer patients by boosting the production of white blood cells, thereby decreasing the risk of chemotherapy-induced neutropenia and allowing for safer, more continuous cancer treatment. For example, in October 2025, the National Health Service (NHS), a UK-based government health agency, recorded 354,820 new cancer diagnoses in 2023, averaging 972 per day, which marks an increase of 8,605 compared to 2022. Therefore, the increasing incidence of cancer is propelling the filgrastim biosimilars market.

Which Segment-Based Categories Are Covered In The Filgrastim Biosimilars Market?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Which Trends Are Affecting The Filgrastim Biosimilars Market Framework?

Major companies in the filgrastim biosimilar market are developing innovative products utilizing advanced technologies, such as recombinant DNA technology, for biosimilar production. Recombinant DNA technology involves the creation of hybrid or chimeric DNA by inserting a foreign genetic sequence into an organism’s DNA. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA, in the United States. This product is indicated for the treatment and prevention of febrile neutropenia. It functions by promoting the expansion and specialization of neutrophils from dedicated precursor cells, initiating their maturation, and improving the viability and efficiency of fully developed neutrophils, leading to dosage-dependent increases in neutrophil counts. The introduction of Fylnetra contributes to the next generation of affordable medicines and enhances access for patients, providers, and payors.

Which Key Players Are Active In The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Access The Complete Filgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Which Region Stands As The Largest Contributor To The Filgrastim Biosimilars Market?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Filgrastim Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Filgrastim Biosimilars Market Expected To Change From 2026 To 2030?

The filgrastim biosimilars market size has experienced substantial growth in recent years. It is projected to expand from $1.19 billion in 2025 to $1.33 billion in 2026, at a compound annual growth rate (CAGR) of 11.5%. This historical growth can be attributed to several factors including the high cost of originator filgrastim, the increasing prevalence of cancer and blood disorders, limited access to biologics in emerging regions, the development of hospital infrastructure, and early approvals of biosimilars by regulatory authorities.

The filgrastim biosimilars market size is projected to experience substantial growth in the coming years, with expectations to reach $2.09 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is primarily due to the introduction of next-generation filgrastim biosimilars, the broadening of contract manufacturing alliances, increasing adoption in chronic and autoimmune diseases, enhanced government support and reimbursement policies, and the development of patient-centric distribution and delivery systems. Significant trends anticipated for this period encompass the growing use of filgrastim biosimilars in oncology and blood disorder treatments, the expansion of contract manufacturing organizations for biosimilar production, a rise in the utilization of in-house vertically integrated manufacturing facilities, an increasing preference for hospital and retail pharmacy distribution channels, and a continued focus on cost-effective biologics along with improved access in emerging markets.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Key Factors Are Affecting The Filgrastim Biosimilars Market Demand?

The filgrastim biosimilars market is anticipated to expand due to the increasing occurrence of cancer. Cancer constitutes a collection of illnesses characterized by the uncontrolled proliferation and dissemination of atypical cells within the body, stemming from genetic alterations that interfere with normal cellular regulation. The growing incidence of cancer is partially attributable to population aging, as extended lifespans increase the probability of developing genetic mutations associated with the disease. Filgrastim biosimilars support cancer patients by stimulating the generation of white blood cells, thereby mitigating the danger of chemotherapy-induced neutropenia, and facilitating safer, uninterrupted cancer therapy. As an illustration, in October 2025, the UK’s National Health Service (NHS) reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, marking an increase of 8,605 from 2022. Consequently, the increased rate of cancer is a key driver for the filgrastim biosimilars market.

Which Segment Types Are Examined In The Filgrastim Biosimilars Market Segment Study?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

What Trends Are Influencing The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilar market are focusing on creating novel products by utilizing sophisticated methods such as recombinant DNA technology for biosimilar production. This recombinant DNA technology entails forming hybrid or chimeric DNA through the insertion of an external genetic sequence into an organism’s DNA. As an illustration, in May 2023, Amneal Pharmaceuticals, a pharmaceutical firm based in the US, introduced FYLNETRA (pegfilgrastim-pbbk) in the United States, serving as a biosimilar alternative to Amgen’s NEULASTA, and prescribed for managing and preventing febrile neutropenia. This product facilitates the proliferation and differentiation of neutrophils derived from specific precursor cells, initiates their development, and enhances the endurance and performance of mature neutrophils, resulting in increases in neutrophil counts dependent on the dosage. The introduction of Fylnetra signifies a step forward in providing more accessible and economical medications, broadening availability for patients, healthcare providers, and insurers alike.

Which Players Are Part Of The Competitive Landscape Of The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Get The Full Filgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Where Is The Filgrastim Biosimilars Market Primarily Concentrated By Region?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Filgrastim Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Filgrastim Biosimilars Market Expected To Change From 2026 To 2030?

The filgrastim biosimilars market size has experienced substantial growth in recent years. It is projected to expand from $1.19 billion in 2025 to $1.33 billion in 2026, at a compound annual growth rate (CAGR) of 11.5%. This historical growth can be attributed to several factors including the high cost of originator filgrastim, the increasing prevalence of cancer and blood disorders, limited access to biologics in emerging regions, the development of hospital infrastructure, and early approvals of biosimilars by regulatory authorities.

The filgrastim biosimilars market size is projected to experience substantial growth in the coming years, with expectations to reach $2.09 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is primarily due to the introduction of next-generation filgrastim biosimilars, the broadening of contract manufacturing alliances, increasing adoption in chronic and autoimmune diseases, enhanced government support and reimbursement policies, and the development of patient-centric distribution and delivery systems. Significant trends anticipated for this period encompass the growing use of filgrastim biosimilars in oncology and blood disorder treatments, the expansion of contract manufacturing organizations for biosimilar production, a rise in the utilization of in-house vertically integrated manufacturing facilities, an increasing preference for hospital and retail pharmacy distribution channels, and a continued focus on cost-effective biologics along with improved access in emerging markets.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Key Factors Are Affecting The Filgrastim Biosimilars Market Demand?

The filgrastim biosimilars market is anticipated to expand due to the increasing occurrence of cancer. Cancer constitutes a collection of illnesses characterized by the uncontrolled proliferation and dissemination of atypical cells within the body, stemming from genetic alterations that interfere with normal cellular regulation. The growing incidence of cancer is partially attributable to population aging, as extended lifespans increase the probability of developing genetic mutations associated with the disease. Filgrastim biosimilars support cancer patients by stimulating the generation of white blood cells, thereby mitigating the danger of chemotherapy-induced neutropenia, and facilitating safer, uninterrupted cancer therapy. As an illustration, in October 2025, the UK’s National Health Service (NHS) reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, marking an increase of 8,605 from 2022. Consequently, the increased rate of cancer is a key driver for the filgrastim biosimilars market.

Which Segment Types Are Examined In The Filgrastim Biosimilars Market Segment Study?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

What Trends Are Influencing The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilar market are focusing on creating novel products by utilizing sophisticated methods such as recombinant DNA technology for biosimilar production. This recombinant DNA technology entails forming hybrid or chimeric DNA through the insertion of an external genetic sequence into an organism’s DNA. As an illustration, in May 2023, Amneal Pharmaceuticals, a pharmaceutical firm based in the US, introduced FYLNETRA (pegfilgrastim-pbbk) in the United States, serving as a biosimilar alternative to Amgen’s NEULASTA, and prescribed for managing and preventing febrile neutropenia. This product facilitates the proliferation and differentiation of neutrophils derived from specific precursor cells, initiates their development, and enhances the endurance and performance of mature neutrophils, resulting in increases in neutrophil counts dependent on the dosage. The introduction of Fylnetra signifies a step forward in providing more accessible and economical medications, broadening availability for patients, healthcare providers, and insurers alike.

Which Players Are Part Of The Competitive Landscape Of The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Get The Full Filgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Where Is The Filgrastim Biosimilars Market Primarily Concentrated By Region?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Filgrastim Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Filgrastim Biosimilars Market Expected To Change From 2026 To 2030?

The filgrastim biosimilars market size has experienced substantial growth in recent years. It is projected to expand from $1.19 billion in 2025 to $1.33 billion in 2026, at a compound annual growth rate (CAGR) of 11.5%. This historical growth can be attributed to several factors including the high cost of originator filgrastim, the increasing prevalence of cancer and blood disorders, limited access to biologics in emerging regions, the development of hospital infrastructure, and early approvals of biosimilars by regulatory authorities.

The filgrastim biosimilars market size is projected to experience substantial growth in the coming years, with expectations to reach $2.09 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period is primarily due to the introduction of next-generation filgrastim biosimilars, the broadening of contract manufacturing alliances, increasing adoption in chronic and autoimmune diseases, enhanced government support and reimbursement policies, and the development of patient-centric distribution and delivery systems. Significant trends anticipated for this period encompass the growing use of filgrastim biosimilars in oncology and blood disorder treatments, the expansion of contract manufacturing organizations for biosimilar production, a rise in the utilization of in-house vertically integrated manufacturing facilities, an increasing preference for hospital and retail pharmacy distribution channels, and a continued focus on cost-effective biologics along with improved access in emerging markets.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Key Factors Are Affecting The Filgrastim Biosimilars Market Demand?

The filgrastim biosimilars market is anticipated to expand due to the increasing occurrence of cancer. Cancer constitutes a collection of illnesses characterized by the uncontrolled proliferation and dissemination of atypical cells within the body, stemming from genetic alterations that interfere with normal cellular regulation. The growing incidence of cancer is partially attributable to population aging, as extended lifespans increase the probability of developing genetic mutations associated with the disease. Filgrastim biosimilars support cancer patients by stimulating the generation of white blood cells, thereby mitigating the danger of chemotherapy-induced neutropenia, and facilitating safer, uninterrupted cancer therapy. As an illustration, in October 2025, the UK’s National Health Service (NHS) reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, marking an increase of 8,605 from 2022. Consequently, the increased rate of cancer is a key driver for the filgrastim biosimilars market.

Which Segment Types Are Examined In The Filgrastim Biosimilars Market Segment Study?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

What Trends Are Influencing The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilar market are focusing on creating novel products by utilizing sophisticated methods such as recombinant DNA technology for biosimilar production. This recombinant DNA technology entails forming hybrid or chimeric DNA through the insertion of an external genetic sequence into an organism’s DNA. As an illustration, in May 2023, Amneal Pharmaceuticals, a pharmaceutical firm based in the US, introduced FYLNETRA (pegfilgrastim-pbbk) in the United States, serving as a biosimilar alternative to Amgen’s NEULASTA, and prescribed for managing and preventing febrile neutropenia. This product facilitates the proliferation and differentiation of neutrophils derived from specific precursor cells, initiates their development, and enhances the endurance and performance of mature neutrophils, resulting in increases in neutrophil counts dependent on the dosage. The introduction of Fylnetra signifies a step forward in providing more accessible and economical medications, broadening availability for patients, healthcare providers, and insurers alike.

Which Players Are Part Of The Competitive Landscape Of The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Get The Full Filgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Where Is The Filgrastim Biosimilars Market Primarily Concentrated By Region?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Filgrastim Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Filgrastim Biosimilars Market Evolve From 2026 To 2030?

The filgrastim biosimilars market has experienced rapid expansion over recent years. This market is projected to expand from $1.19 billion in 2025 to $1.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. Historically, this growth can be ascribed to several factors, including the elevated cost of originator filgrastim, the rising incidence of cancer and blood disorders, restricted access to biologics in developing areas, expanding hospital infrastructure, and the timely approval of biosimilars by regulatory bodies.

The filgrastim biosimilars market is projected to expand significantly over the coming years. This market is anticipated to reach a value of $2.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. Key factors driving this expansion during the forecast period include the introduction of advanced filgrastim biosimilars, an increase in contract manufacturing collaborations, greater uptake in the management of chronic and autoimmune conditions, enhanced government backing and favorable reimbursement frameworks, and the evolution of distribution and delivery systems focused on patients. Significant developments expected in this timeframe involve the growing use of filgrastim biosimilars in cancer and blood disorder therapies, the enlargement of contract manufacturing organizations dedicated to biosimilar production, a rise in the utilization of internal vertically integrated manufacturing sites, a stronger inclination towards hospital and retail pharmacy distribution routes, and a strategic emphasis on affordable biologics and market penetration in developing regions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Major Drivers Are Influencing Demand In The Filgrastim Biosimilars Market?

The increasing occurrence of cancer is projected to propel the expansion of the filgrastim biosimilars market in the future. Cancer encompasses a range of illnesses characterized by the unchecked proliferation and dissemination of atypical cells within the body, stemming from genetic alterations that impair typical cellular control. The rising rate of cancer diagnoses can be partially attributed to the aging global population, as extended lifespans correlate with an elevated probability of developing cancer-causing genetic mutations. Filgrastim biosimilars assist individuals with cancer by stimulating the generation of white blood cells, thereby lowering the danger of neutropenia caused by chemotherapy, and facilitating more secure and uninterrupted cancer therapies. For example, data from October 2025, reported by the National Health Service (NHS), a UK-based government health agency, indicated 354,820 new cancer diagnoses in 2023, averaging 972 cases daily, which represented an increase of 8,605 compared to 2022. Consequently, the growing prevalence of cancer is actively driving the filgrastim biosimilars market.

Which Segment Areas Are Covered In The Filgrastim Biosimilars Market Analysis?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

What Key Developments And Trends Are Impacting The Filgrastim Biosimilars Market?

Prominent companies in the filgrastim biosimilar market are creating innovative products utilizing advanced technologies, such as recombinant DNA technology, for biosimilar manufacturing. Recombinant DNA technology is a procedure characterized by the formation of hybrid or chimeric DNA through the insertion of an external sequence into an organism’s DNA. For example, Amneal Pharmaceuticals, a US-based pharmaceutical firm, introduced FYLNETRA (pegfilgrastim-pbbk) in the United States in May 2023. This product, a biosimilar to Amgen’s NEULASTA, is indicated for managing and preventing febrile neutropenia. It encourages the proliferation and specialization of neutrophils originating from specific precursor cells, initiates their maturation, and enhances the vitality and performance of developed neutrophils, leading to increases in neutrophil counts proportional to the dosage. The release of Fylnetra contributes to the next generation of affordable medications and expands access for patients, providers, and payors alike.

Which Global Companies Are Actively Competing In The Filgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Read the full filgrastim biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Filgrastim Biosimilars Market?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Filgrastim Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=4016&type=smp

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the filgrastim biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Filgrastim Biosimilars Market?

The filgrastim biosimilars market size has seen rapid expansion in recent years. It is anticipated to expand from $1.19 billion in 2025 to $1.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.5%. Historically, this growth can be ascribed to the elevated cost of originator filgrastim, the increasing occurrence of cancer and blood disorders, restricted access to biologics in developing regions, advancing hospital infrastructure, and prompt approvals of biosimilars by regulatory bodies.

The filgrastim biosimilars market is anticipated to undergo significant expansion in the coming years, with its valuation projected to reach $2.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This projected growth during the forecast period is primarily driven by the introduction of next-generation filgrastim biosimilars, the expansion of contract manufacturing alliances, increased adoption in chronic and autoimmune diseases, growing government backing and reimbursement policies, and the development of patient-centric distribution and delivery models. Important trends for this period include the rising acceptance of filgrastim biosimilars in oncology and blood disorder treatments, the proliferation of contract manufacturing organizations for biosimilar production, an increased reliance on in-house vertically integrated manufacturing facilities, a developing preference for hospital and retail pharmacy distribution channels, and a focus on cost-effective biologics and improved access in emerging markets.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Drivers Are Supporting Technological Adoption In The Filgrastim Biosimilars Market?

An escalating incidence of cancer is anticipated to fuel the expansion of the filgrastim biosimilars market moving forward. Cancer describes a collection of diseases distinguished by the unregulated multiplication and dissemination of abnormal cells within the body, triggered by genetic alterations that interfere with normal cellular regulation. The increase in cancer cases is partially attributed to an aging global population, as individuals living longer face a higher probability of acquiring genetic mutations that contribute to cancer development. Filgrastim biosimilars provide support to cancer patients by stimulating white blood cell production, thereby reducing the danger of neutropenia induced by chemotherapy and enabling safer, more consistent cancer treatment. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which signifies an increase of 8,605 compared to 2022. Hence, the increasing occurrence of cancer is a key driver for the filgrastim biosimilars market.

What Segment Types Are Examined In The Filgrastim Biosimilars Market?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Which Trends Are Expected To Influence The Filgrastim Biosimilars Market In The Upcoming Years?

Leading companies in the filgrastim biosimilar market are innovating products with advanced methods like recombinant DNA technology for biosimilar creation. Recombinant DNA technology is a procedure where hybrid or chimeric DNA is formed by inserting a foreign sequence into an organism’s DNA. For example, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, introduced FYLNETRA (pegfilgrastim-pbbk) in the United States. This biosimilar to Amgen’s NEULASTA is prescribed for addressing and preventing febrile neutropenia. It encourages the proliferation and differentiation of neutrophils from specific precursor cells, prompts their development, and boosts the vitality and functionality of mature neutrophils, thereby causing dose-dependent increases in neutrophil counts. The release of Fylnetra contributes to a new phase of accessible medicines and expands availability for patients, healthcare providers, and payors.

Who Are The Prominent Global Companies Shaping The Filgrastim Biosimilars Market Landscape?

Major companies operating in the filgrastim biosimilars market are Teva Pharmaceutical Industries Ltd, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., Tonghua Dongbaoare, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Filgrastim Biosimilars Market?

North America was the largest region in the filgrastim biosimilar markets market in 2025. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Filgrastim Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=4016&type=smp

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2026, By The Business Research Company

Neutropenia Biologic Drug Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

G Csf Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Pegfilgrastim Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the filgrastim biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Current and Projected Market Size of the Filgrastim Biosimilars Market Through 2034?

The market for filgrastim biosimilars has seen robust growth in the past few years. The market value is estimated to escalate from $0.92 billion in 2024 to approximately $0.98 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.9%. This growth noted in the previous period is associated with the rise in emerging markets, an increase in patent expiration, government initiatives, escalated healthcare expenditure, reduced biosimilars costs, a reliable drug pipeline, and a surge in biopharmaceutical R&D spending.

The market size for filgrastim biosimilars is predicted to exhibit robust growth in the upcoming years, achieving a worth of $1.21 billion in 2029 with a compound annual growth rate (CAGR) of 5.4%. The growth during the forecast period is due to factors such as an aging population and expanded access to healthcare. Dominant trends anticipated in the forecast period involve considerable investment into Research & Development for generating innovative and effective biosimilars, the manufacture of biosimilars for neutropenia treatment to boost revenues, and enhanced focus on mergers and acquisitions as growth strategies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Filgrastim Biosimilars Market?

The uptick seen in cases of neutropenia is anticipated to push forward the expansion of the filgrastim biosimilar market. Neutropenia is an ailment characterized by low levels of neutrophils, a crucial type of white blood cell that combats infections. Filgrastim biosimilars enhance the production of neutrophils in our bone marrow, increasing the neutrophil count and helping to combat infections. For example, data from the National Center for Biotechnology Information, a US biomedical literature database, showed that in August 2022, the frequency of neutropenia was 0.38% in Mexican-Americans, 0.79% in whites, and 4.5% in black participants. Consequently, the rising occurrence of neutropenia is fuelling the progression of the filgrastim biosimilar market.

Which Key Market Segments Comprise the Filgrastim Biosimilars Market and Drive Its Revenue Growth?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=4016&type=smp

Which Areas Are Leading Regions in the Filgrastim Biosimilars Market Expansion Across the Globe?

North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Strategic Trends Steering theFilgrastim Biosimilars Market Direction?

Major firms in the filgrastim biosimilar market are focusing on the creation of innovative products that incorporate advanced technologies, such as recombinant DNA technology, into their biosimilars production. This technique involves the generation of hybrid or chimeric DNA by integrating a foreign sequence into an organism’s DNA. To illustrate, in May 2023, Amneal Pharmaceuticals, located in the US, introduced FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA. The product was launched in the US with an indication for the treatment and prevention of febrile neutropenia. It enhances the expansion and specialization of precursor cells-derived neutrophils, induces their maturation, and increases the survival and efficacy of fully mature neutrophils, leading to neutrophil count increases dependent on dosage. The introduction of Fylnetra fosters the next generation of cost-effective medicines and promotes widespread accessibility for patients, healthcare providers, and payors.

View the full report here:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

How Is the Filgrastim Biosimilars Market Conceptually Defined?

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4016

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theFilgrastim Biosimilars Market?

An upsurge in neutropenia prevalence is forecasted to amplify the growth of the filgrastim biosimilar market in the future. Neutropenia is a condition characterized by a deficiency of neutrophils, a significant type of white blood cell responsible for fighting infections. Filgrastim biosimilars function to increase the production of neutrophils in the bone marrow, thereby boosting the neutrophil count to aid in infection combat. For example, as stated by the US-based biomedical literature database, the National Center for Biotechnology Information, in August 2022, the incidence of neutropenia was 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Consequently, the escalating incidence of neutropenia is fueling the expansion of the filgrastim biosimilar market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

#What is the Anticipated CAGR of theFilgrastim Biosimilars Market, and What Factors Will Drive It?

In recent times, the filgrastim biosimilars market has seen substantial growth. The market, which will climb from $0.92 billion in 2024 to $0.98 billion in 2025, is expected to enjoy a compound annual growth rate (CAGR) of 6.9%. Factors that have contributed to growth in the past include expansion in emerging markets, rise in patent expirations, governmental measures, heightened healthcare expenditure, reduced biosimilar costs, a robust drug pipeline, and increased expenditure on biopharmaceutical research and development.

Over the next several years, a robust expansion is projected for the filgrastim biosimilars market, which is expected to be valued at $1.21 billion by 2029, registering a compound annual growth rate (CAGR) of 5.4%. This growth is due to factors such as the aging populace, and increased access to healthcare. The forecast period is set to see key trends such as massive investment in research and development for the generation of innovative and effective biosimilars, manufacturing biosimilars for the treatment of neutropenia to enhance revenue, and a growing emphasis on M&A strategies to spur growth.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4016

Which Upcoming Market Trends and Innovations Are Set to Influence theFilgrastim Biosimilars Market’s Path Forward?

Leading businesses in the filgrastim biosimilar market are pioneering novel products employing cutting-edge techniques such as recombinant DNA technology for biosimilars production. This method entails forming hybrid or chimeric DNA by integrating a foreign chain into an organism’s DNA. For example, in May 2023, Amneal Pharmaceuticals, renowned US-based pharmaceutical firm, introduced FYLNETRA (pegfilgrastim-pbbk) in the US market, a biosimilar to Amgen’s NEULASTA, prescribed for febrile neutropenia prevention and treatment. It aids in the growth and specialization of neutrophils descending from specific precursor cells, encourages their advancement, and enhances the survival and effectiveness of fully matured neutrophils, causing dosage-dependent increases in neutrophil counts. The introduction of Fylnetra marks the onset of a new batch of cost-effective medicines, promoting accessibility for patients, care providers, and payors.

Who Are the Dominant Market Players Pushing the Boundaries of theFilgrastim Biosimilars Market?

Major companies operating in the filgrastim biosimilars market include Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy’s Laboratories, Pfizer, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Fuji Pharma, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

What Are the Core Segments of the Filgrastim Biosimilars Market, and How Do They Contribute to Growth?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=4016&type=smp

What Regions Are Dominating the Filgrastim Biosimilars Market Growth?

North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Filgrastim Biosimilars Market 2025, By The Business Research Company:

IVF Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ivf-services-global-market-report

Fertility Treatments Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Robotic Surgery Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/robotic-surgery-services-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: